Recurrent heart failure with preserved ejection fraction associated with carfilzomib administration for multiple myeloma

Carfilzomib, an epoxyketone proteasome inhibitor, has demonstrated improved progression-free survival in patients when used with standard treatment (lenalidomide and dexamethasone) in patients with relapsed multiple myeloma (MM). However, there are reports of adverse cardiac events with carfilzomib...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Eric H., Courtney, Cynthia, Garg, Vinisha, Fradley, Michael G., Schiller, Gary J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7048019/
https://www.ncbi.nlm.nih.gov/pubmed/32154003
http://dx.doi.org/10.1186/s40959-018-0028-z
_version_ 1783502221643612160
author Yang, Eric H.
Courtney, Cynthia
Garg, Vinisha
Fradley, Michael G.
Schiller, Gary J.
author_facet Yang, Eric H.
Courtney, Cynthia
Garg, Vinisha
Fradley, Michael G.
Schiller, Gary J.
author_sort Yang, Eric H.
collection PubMed
description Carfilzomib, an epoxyketone proteasome inhibitor, has demonstrated improved progression-free survival in patients when used with standard treatment (lenalidomide and dexamethasone) in patients with relapsed multiple myeloma (MM). However, there are reports of adverse cardiac events with carfilzomib manifested by dyspnea and heart failure. A patient is presented who had recurrent, clinically mild cardiotoxicity, as manifested by recurrent heart failure with preserved ejection fraction, with ongoing maintenance carfilzomib in a patient with resistant MM is presented.
format Online
Article
Text
id pubmed-7048019
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-70480192020-03-09 Recurrent heart failure with preserved ejection fraction associated with carfilzomib administration for multiple myeloma Yang, Eric H. Courtney, Cynthia Garg, Vinisha Fradley, Michael G. Schiller, Gary J. Cardiooncology Short Communication Carfilzomib, an epoxyketone proteasome inhibitor, has demonstrated improved progression-free survival in patients when used with standard treatment (lenalidomide and dexamethasone) in patients with relapsed multiple myeloma (MM). However, there are reports of adverse cardiac events with carfilzomib manifested by dyspnea and heart failure. A patient is presented who had recurrent, clinically mild cardiotoxicity, as manifested by recurrent heart failure with preserved ejection fraction, with ongoing maintenance carfilzomib in a patient with resistant MM is presented. BioMed Central 2018-03-01 /pmc/articles/PMC7048019/ /pubmed/32154003 http://dx.doi.org/10.1186/s40959-018-0028-z Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Short Communication
Yang, Eric H.
Courtney, Cynthia
Garg, Vinisha
Fradley, Michael G.
Schiller, Gary J.
Recurrent heart failure with preserved ejection fraction associated with carfilzomib administration for multiple myeloma
title Recurrent heart failure with preserved ejection fraction associated with carfilzomib administration for multiple myeloma
title_full Recurrent heart failure with preserved ejection fraction associated with carfilzomib administration for multiple myeloma
title_fullStr Recurrent heart failure with preserved ejection fraction associated with carfilzomib administration for multiple myeloma
title_full_unstemmed Recurrent heart failure with preserved ejection fraction associated with carfilzomib administration for multiple myeloma
title_short Recurrent heart failure with preserved ejection fraction associated with carfilzomib administration for multiple myeloma
title_sort recurrent heart failure with preserved ejection fraction associated with carfilzomib administration for multiple myeloma
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7048019/
https://www.ncbi.nlm.nih.gov/pubmed/32154003
http://dx.doi.org/10.1186/s40959-018-0028-z
work_keys_str_mv AT yangerich recurrentheartfailurewithpreservedejectionfractionassociatedwithcarfilzomibadministrationformultiplemyeloma
AT courtneycynthia recurrentheartfailurewithpreservedejectionfractionassociatedwithcarfilzomibadministrationformultiplemyeloma
AT gargvinisha recurrentheartfailurewithpreservedejectionfractionassociatedwithcarfilzomibadministrationformultiplemyeloma
AT fradleymichaelg recurrentheartfailurewithpreservedejectionfractionassociatedwithcarfilzomibadministrationformultiplemyeloma
AT schillergaryj recurrentheartfailurewithpreservedejectionfractionassociatedwithcarfilzomibadministrationformultiplemyeloma

Ejemplares similares